GLP-1 RA Eligibility in Reproductive-Age U.S. Women
Diabetes Obesity and Cardiometabolic CARE · 01.03.2026 · 1 (2) · 198-202
DOI: 10.2337/doc25-0040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Obesity and Cardiometabolic CARE, online erschienen am 13.03.2026. Verfasst von Ivy Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
OBJECTIVE Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for diabetes or weight management may affect pregnancy outcomes. We sought to estimate the number of U.S. women of reproductive age eligible for GLP-1 RA therapy. RESEARCH DESIGN AND METHODS Using 2017–2023 nationally representative survey data, we identified nonpregnant U.S. women aged 18–44 years who met trial-based eligibility criteria for diabetes, weight management, or secondary cardiovascular prevention. RESULTS Among 3,218 participants, 1,447 were eligible for GLP-1 RAs, representing 24.6 million U.S. women. Among GLP-1 RA–eligible women, mean BMI was 34.8 kg/m2, 8.3% had diabetes, and 1.9% had prior cardiovascular disease. Eligibility was primarily for weight management (24.1 million), followed by diabetes (2.0 million) and cardiovascular prevention (0.34 million). CONCLUSIONS Nearly half of U.S. reproductive-age women are eligible for GLP-1 RAs. Given limited pregnancy safety data and rising cardiometabolic burden in reproductive-age women, research is needed to guide counseling and coverage of preconception GLP-1 RA use.
Autor:innen und Institutionen
- Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA.
- Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
- Department of Medicine and Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.
- Division of General Obstetrics and Gynecology, Brown University, Providence, RI.
- Division of Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
ORCID-Profile: Ivy Shi, Sadiya S Khan, Dhruv S Kazi
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Shi, I., Khan, S. S., Grobman, W., & Kazi, D. S. (2026). GLP-1 RA Eligibility in Reproductive-Age U.S. Women. Diabetes Obesity and Cardiometabolic CARE, 1(2), 198-202. https://doi.org/10.2337/doc25-0040
Vancouver
Shi I, Khan SS, Grobman W, Kazi DS. GLP-1 RA Eligibility in Reproductive-Age U.S. Women. Diabetes Obesity and Cardiometabolic CARE. 2026;1(2):198-202. doi:10.2337/doc25-0040
BibTeX
@article{Shi2026,
author = {Shi, Ivy and Khan, Sadiya S and Grobman, William and Kazi, Dhruv S},
title = {GLP-1 RA Eligibility in Reproductive-Age U.S. Women},
journal = {Diabetes Obesity and Cardiometabolic CARE},
year = {2026},
volume = {1},
number = {2},
pages = {198--202},
doi = {10.2337/doc25-0040}
}
EUVIMED